Bristol-Myers Squibb Company (BMY) AGM 2026 summary

Opening remarks and agenda

• The meeting was called to order with all board members and key leadership present, and a quorum established with over 86% of shares represented virtually or by proxy.

• Shareholders were welcomed and informed about the agenda, voting procedures, and the opportunity to submit questions in advance or during the meeting.

Financial performance review

• Total revenues for 2025 reached $48.2 billion, with the growth portfolio accounting for over half and increasing 17% from 2024.

• Seven products in the growth portfolio now generate over $1 billion each in annual sales; BREYANZI, OPDUALAG, and CAMZYOS surpassed $1 billion, REBLOZYL exceeded $2 billion.

• Despite a $4 billion decline in legacy portfolio revenue, growth portfolio nearly offset the loss.

• Achieved $10 billion debt paydown ahead of schedule and marked the 93rd consecutive year of dividend payments.

Board and executive committee updates

• All 11 directors were up for re-election for one-year terms expiring at the 2027 annual meeting.

• The board reaffirmed its commitment to annual governance structure reviews and maintaining flexibility in leadership roles.